|Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2|
J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, ...
New England Journal of Medicine 369 (25), 2391-2405, 2013
|Effect of mutation order on myeloproliferative neoplasms|
CA Ortmann, DG Kent, J Nangalia, Y Silber, DC Wedge, J Grinfeld, ...
New England Journal of Medicine 372 (7), 601-612, 2015
|Classification and personalized prognosis in myeloproliferative neoplasms|
J Grinfeld, J Nangalia, EJ Baxter, DC Wedge, N Angelopoulos, R Cantrill, ...
New England Journal of Medicine 379 (15), 1416-1430, 2018
|Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer|
YS Ju, LB Alexandrov, M Gerstung, I Martincorena, S Nik-Zainal, ...
elife 3, e02935, 2014
|The mutational landscape of normal human endometrial epithelium|
L Moore, D Leongamornlert, THH Coorens, MA Sanders, P Ellis, ...
Nature 580 (7805), 640-646, 2020
|Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial|
RA Mesa, AM Vannucchi, A Mead, M Egyed, A Szoke, A Suvorov, ...
The Lancet Haematology 4 (5), e225-e236, 2017
|Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms|
W Tapper, AV Jones, R Kralovics, AS Harutyunyan, K Zoi, W Leung, ...
Nature communications 6 (1), 1-11, 2015
|Pan-cancer analysis of whole genomes.|
S Hirano, L Yang, M Juul, CA Purdie, BP O'Neill, R Kabbe, ...
Nature 578 (DKFZ-2020-01051), 82-93, 2020
|Inactivating CUX1 mutations promote tumorigenesis|
CC Wong, I Martincorena, AG Rust, M Rashid, C Alifrangis, ...
Nature genetics 46 (1), 33-38, 2014
|Myeloproliferative neoplasms: from origins to outcomes|
J Nangalia, AR Green
Hematology 2014, the American Society of Hematology Education Program Book …, 2017
|Extensive heterogeneity in somatic mutation and selection in the human bladder|
ARJ Lawson, F Abascal, THH Coorens, Y Hooks, L O’Neill, C Latimer, ...
Science 370 (6512), 75-82, 2020
|A guideline for the diagnosis and management of polycythaemia vera|
MF McMullin, CN Harrison, S Ali, C Cargo, F Chen, J Ewing, M Garg, ...
British journal of haematology 184 (2), 176-191, 2019
|DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype|
J Nangalia, FL Nice, DC Wedge, AL Godfrey, J Grinfeld, C Thakker, ...
Haematologica 100 (11), e438, 2015
|The evolving genomic landscape of myeloproliferative neoplasms|
J Nangalia, TR Green
Hematology 2014, the American Society of Hematology Education Program Book …, 2014
|Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms|
J Grinfeld, J Nangalia, AR Green
Haematologica 102 (1), 7, 2017
|JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease|
J Li, DG Kent, AL Godfrey, H Manning, J Nangalia, A Aziz, E Chen, ...
Blood, The Journal of the American Society of Hematology 123 (20), 3139-3151, 2014
|Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells|
YS Ju, JMC Tubio, W Mifsud, B Fu, HR Davies, M Ramakrishna, Y Li, ...
Genome research 25 (6), 814-824, 2015
|Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms|
AV Jones, D Ward, M Lyon, W Leung, A Callaway, A Chase, CL Dent, ...
Leukemia research 39 (1), 82-87, 2015
|BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms|
BS Wyspiańska, AJ Bannister, I Barbieri, J Nangalia, A Godfrey, ...
Leukemia 28 (1), 88-97, 2014
|Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-Å structure of the heparin-bridged complex|
W Li, TE Adams, J Nangalia, CT Esmon, JA Huntington
Proceedings of the National Academy of Sciences 105 (12), 4661-4666, 2008